Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Actavis May Sell Bioton’s Insulin As Companies Plan to Sign Deal

Don't Miss Out —
Follow us on:

Nov. 15 (Bloomberg) -- Actavis Group hf, an Iceland-based maker of generic drugs, and Bioton SA, a Polish insulin producer, plan to sign a cooperation agreement by the end of this year, Bioton said in a regulatory statement yesterday.

Upon the deal Actavis will be responsible for distributing Bioton’s products, with both companies participating equally in costs and profits of the project.

Actavis will pay Bioton one-off compensation that won’t exceed 500 million zloty ($174 million), the Warsaw-based company said, adding that the exact amount will be set in the final agreement.

Link to Statement:{NSN LBVZG53PWT1C <GO>}

Link to Company News:{ACT IR <Equity> CN <GO>} Link to Company News:{BIO PW <Equity> CN <GO>}

To contact the editor responsible for this story: Maciej Martewicz at mmartewicz@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.